The Journal of antimicrobial chemotherapy
Journal
Overview
publication venue for
-
Characterization of a novel carbapenem-hydrolysing β-lactamase OXA-1041 in Escherichia coli..
78.
2023
-
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
2021
-
SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study..
76.
2021
-
Apramycin resistance in epidemic carbapenem-resistant Klebsiella pneumoniae ST258 strains..
76.
2021
-
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital..
76.
2021
-
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar..
74.
2019
-
Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy..
74.
2019
-
In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium..
74.
2019
-
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353..
74.
2019
-
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate..
73.
2018
-
Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs..
73.
2018
-
Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA..
72.
2017
-
Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae..
72.
2017
-
Rise and fall of KPC-producing Klebsiella pneumoniae in New York City..
71.
2016
-
Heterogeneous oxacillin-resistant phenotypes and production of PBP2A by oxacillin-susceptible/mecA-positive MRSA strains from Africa..
71.
2016
-
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints..
71.
2016
-
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease..
71.
2015
-
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response..
70.
2015
-
In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms..
70.
2014
-
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti..
69.
2014
-
Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application..
69.
2013
-
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs..
68.
2013
-
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques..
68.
2012
-
Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220..
68.
2012
-
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials..
67.
2012
-
Impact of antimicrobial stewardship programme changes on unnecessary double anaerobic coverage therapy..
66.
2011
-
Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring bla(KPC) from New York City and Toronto..
66.
2011
-
Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline..
65.
2010
-
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA..
63.
2009
-
Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits..
56.
2005
-
Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus..
54.
2004
-
Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002..
54 Suppl 1.
2004
-
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia..
54.
2004
-
Emergence of fluoroquinolone resistance among Bacteroides species..
52.
2003
-
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents..
52.
2003
-
In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms..
51.
2003
-
Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants..
50.
2002
-
Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model..
50.
2002
-
A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting..
49.
2002
-
Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors..
49.
2002
-
The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin..
46.
2000
-
Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis..
44.
1999
-
Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group..
43.
1999
-
Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens..
41.
1998
-
Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis..
39 Suppl A.
1997
-
Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics..
39 Suppl A.
1997
-
Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin..
37.
1996
-
Enhancement of drug susceptibility of multi-drug resistant strains of Mycobacterium tuberculosis by ethambutol and dimethyl sulphoxide..
35.
1995
-
Lytic and bactericidal activity of FCE 22101..
23 Suppl C.
1989
-
Successful treatment of candida peritonitis with fluconazole.
1994
-
Adjunctive therapies for community-acquired pneumonia: a systematic review.
2008
-
Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis.
2007
-
From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae.
2002
-
Molecular aspects of methicillin resistance in Staphylococcus aureus.
1994
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)